Stockreport

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study [Yahoo! Finance]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF from the Phase 2 study of its investigational gene-editing therapy, NTLA-2002, for hereditary angioedema (HAE). Despite the data indicating a reduction in HAE attacks, [Read more]